Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shenzhen's BGI Has Revamped Plans for $600 Million China IPO

publication date: Apr 13, 2016
BGI, the Shenzhen genomic sequencing powerhouse, is once again proposing an IPO: this time the company intends to list two of its units, BGI Dx and BGI Tech, on the Shenzhen ChiNext exchange. A preliminary prospectus, filed in December 2015, placed a $3 billion valuation on the two subsidiaries, which have been merged. The IPO is expected to offer a 20% stake of the merged entity -- $600 million. BGI Tech provides contract sequencing to life science companies. BGI Dx offers clinical screening tests, especially non-invasive prenatal tests in China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here